Ipsen Biopharmaceuticals, Inc.
1 Main Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
471 articles with Ipsen Biopharmaceuticals, Inc.
Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP
Health Canada Approves Ipsen's CABOMETYX™ (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma
CABOMETYXTM demonstrated a statistically significant, 52 per cent reduction in the risk of progression or death compared with sunitinibi, giving Canadian patients with intermediate or poor risk a new oral first-line treatment option in their fight against advanced kidney cancer
9/30/2019It was a moderately busy week for clinical trial news. Here’s a look.
Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy
Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced that the United States Food and Drug Administration has expanded the use of Dysport® for injection to include the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy.
Ipsen Showcases Studies at the ESMO 2019 Congress Highlighting Progress in New Approaches for Difficult-to-Treat Cancers
Presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors
Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis1,2,3,4
Results presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Nice, France, 22-26 September 2019
Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a Guided Self-rehabilitation Contract.
Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer
Ipsen and Servier announced initial safety and efficacy data from Part 1 of the Phase II/III RESILIENT study of investigational liposomal irinotecan in patients with small cell lung cancer who progressed following a first-line platinum-based regimen.
Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019
Ipsen, a global specialty-driven biopharmaceutical group, announced financial results for the first half of 2019.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint)
Ipsen Announces U.S. FDA Approval for Newly Designed Pre-Filled Syringe for Somatuline® Depot (lanreotide)
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a new pre-filled syringe for Somatuline® Depot (lanreotide).
Ipsen officially opens North American headquarters at One Main Street and recently renovated R&D and Global External Innovation and Partnering facilities at 650 East Kendall Street
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting
Ipsen announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib, liposomal irinotecan, and lanreotide autogel will be presented at the 2019 American Society of Clinical Oncology Annual Meeting.
Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022
Ipsen, a global specialty-driven biopharmaceutical group, will host an Investor Day in Paris to present a comprehensive corporate update, with a focus on its advancing R&D pipeline.
Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets
Ipsen, a global specialty-driven biopharmaceutical group, announced its sales for the first quarter of 2019.
Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Clementia Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by French drugmaker Ipsen.
Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Studies Demonstrate Ipsen’s Ongoing Commitment to Innovation and Improving Patient Care in Neuroendocrine Tumors (NETs)